The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial

Leon Adams; D.H.G. Crawford; K.A. Stuart; Mike House; Tim St. Pierre; M. Webb; H.L.I. Ching; J. Kava; M. Bynevelt; Gerry Macquillan; George Garas; O.T. Ayonrinde; Trevor Mori; Kevin Croft; Xianwa Niu; Gary Jeffrey; J.K. Olynyk

doi:10.1002/hep.27662

The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial

Leon Adams, D.H.G. Crawford, K.A. Stuart, Mike House, Tim St. Pierre, M. Webb, H.L.I. Ching, J. Kava, M. Bynevelt, Gerry Macquillan, George Garas, O.T. Ayonrinde, Trevor Mori, Kevin Croft, Xianwa Niu, Gary Jeffrey, J.K. Olynyk

Research output: Contribution to journal › Article

57 Citations (Scopus)

Abstract

© 2014 by the American Association for the Study of Liver Diseases. Iron is implicated in the pathogenesis of liver injury and insulin resistance (IR) and thus phlebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD). We performed a prospective 6-month randomized, controlled trial examining the impact of phlebotomy on the background of lifestyle advice in patients with NAFLD. Primary endpoints were hepatic steatosis (HS; quantified by magnetic resonance imaging) and liver injury (determined by alanine aminotransaminase [ALT] and cytokeratin-18 [CK-18]). Secondary endpoints included insulin resistance measured by the insulin sensitivity index (ISI) and homeostasis model of assessment (HOMA), and systemic lipid peroxidation determined by plasma F2-isoprostane levels. A total of 74 subjects were randomized (33 phlebotomy and 41 control). The phlebotomy group underwent a median (range) of 7 (1-19) venesection sessions and had a significantly greater reduction in ferritin levels over 6 months, compared to controls (-148±114 vs. -38±89 ng/mL; P

Original language	English
Pages (from-to)	1555-1564
Journal	Hepatology
Volume	61
Issue number	5
DOIs	https://doi.org/10.1002/hep.27662
Publication status	Published - 2015

Fingerprint

Cite this

Adams, L., Crawford, D. H. G., Stuart, K. A., House, M., St. Pierre, T., Webb, M., ... Olynyk, J. K. (2015). The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology, 61(5), 1555-1564. https://doi.org/10.1002/hep.27662

Adams, Leon ; Crawford, D.H.G. ; Stuart, K.A. ; House, Mike ; St. Pierre, Tim ; Webb, M. ; Ching, H.L.I. ; Kava, J. ; Bynevelt, M. ; Macquillan, Gerry ; Garas, George ; Ayonrinde, O.T. ; Mori, Trevor ; Croft, Kevin ; Niu, Xianwa ; Jeffrey, Gary ; Olynyk, J.K. / The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. In: Hepatology. 2015 ; Vol. 61, No. 5. pp. 1555-1564.

@article{a944881a16ed43859609b313a6bb5d38,

title = "The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial",

abstract = "{\circledC} 2014 by the American Association for the Study of Liver Diseases. Iron is implicated in the pathogenesis of liver injury and insulin resistance (IR) and thus phlebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD). We performed a prospective 6-month randomized, controlled trial examining the impact of phlebotomy on the background of lifestyle advice in patients with NAFLD. Primary endpoints were hepatic steatosis (HS; quantified by magnetic resonance imaging) and liver injury (determined by alanine aminotransaminase [ALT] and cytokeratin-18 [CK-18]). Secondary endpoints included insulin resistance measured by the insulin sensitivity index (ISI) and homeostasis model of assessment (HOMA), and systemic lipid peroxidation determined by plasma F2-isoprostane levels. A total of 74 subjects were randomized (33 phlebotomy and 41 control). The phlebotomy group underwent a median (range) of 7 (1-19) venesection sessions and had a significantly greater reduction in ferritin levels over 6 months, compared to controls (-148±114 vs. -38±89 ng/mL; P",

author = "Leon Adams and D.H.G. Crawford and K.A. Stuart and Mike House and {St. Pierre}, Tim and M. Webb and H.L.I. Ching and J. Kava and M. Bynevelt and Gerry Macquillan and George Garas and O.T. Ayonrinde and Trevor Mori and Kevin Croft and Xianwa Niu and Gary Jeffrey and J.K. Olynyk",

year = "2015",

doi = "10.1002/hep.27662",

language = "English",

volume = "61",

pages = "1555--1564",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley & Sons",

number = "5",

}

Adams, L, Crawford, DHG, Stuart, KA, House, M , St. Pierre, T, Webb, M, Ching, HLI, Kava, J, Bynevelt, M, Macquillan, G , Garas, G , Ayonrinde, OT , Mori, T , Croft, K, Niu, X, Jeffrey, G & Olynyk, JK 2015, 'The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial' Hepatology, vol. 61, no. 5, pp. 1555-1564. https://doi.org/10.1002/hep.27662

The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. / Adams, Leon; Crawford, D.H.G.; Stuart, K.A.; House, Mike ; St. Pierre, Tim; Webb, M.; Ching, H.L.I.; Kava, J.; Bynevelt, M.; Macquillan, Gerry ; Garas, George ; Ayonrinde, O.T.; Mori, Trevor ; Croft, Kevin; Niu, Xianwa; Jeffrey, Gary; Olynyk, J.K.

In: Hepatology, Vol. 61, No. 5, 2015, p. 1555-1564.

Research output: Contribution to journal › Article

TY - JOUR

T1 - The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial

AU - Adams, Leon

AU - Crawford, D.H.G.

AU - Stuart, K.A.

AU - House, Mike

AU - St. Pierre, Tim

AU - Webb, M.

AU - Ching, H.L.I.

AU - Kava, J.

AU - Bynevelt, M.

AU - Macquillan, Gerry

AU - Garas, George

AU - Ayonrinde, O.T.

AU - Mori, Trevor

AU - Croft, Kevin

AU - Niu, Xianwa

AU - Jeffrey, Gary

AU - Olynyk, J.K.

PY - 2015

Y1 - 2015

N2 - © 2014 by the American Association for the Study of Liver Diseases. Iron is implicated in the pathogenesis of liver injury and insulin resistance (IR) and thus phlebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD). We performed a prospective 6-month randomized, controlled trial examining the impact of phlebotomy on the background of lifestyle advice in patients with NAFLD. Primary endpoints were hepatic steatosis (HS; quantified by magnetic resonance imaging) and liver injury (determined by alanine aminotransaminase [ALT] and cytokeratin-18 [CK-18]). Secondary endpoints included insulin resistance measured by the insulin sensitivity index (ISI) and homeostasis model of assessment (HOMA), and systemic lipid peroxidation determined by plasma F2-isoprostane levels. A total of 74 subjects were randomized (33 phlebotomy and 41 control). The phlebotomy group underwent a median (range) of 7 (1-19) venesection sessions and had a significantly greater reduction in ferritin levels over 6 months, compared to controls (-148±114 vs. -38±89 ng/mL; P

AB - © 2014 by the American Association for the Study of Liver Diseases. Iron is implicated in the pathogenesis of liver injury and insulin resistance (IR) and thus phlebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD). We performed a prospective 6-month randomized, controlled trial examining the impact of phlebotomy on the background of lifestyle advice in patients with NAFLD. Primary endpoints were hepatic steatosis (HS; quantified by magnetic resonance imaging) and liver injury (determined by alanine aminotransaminase [ALT] and cytokeratin-18 [CK-18]). Secondary endpoints included insulin resistance measured by the insulin sensitivity index (ISI) and homeostasis model of assessment (HOMA), and systemic lipid peroxidation determined by plasma F2-isoprostane levels. A total of 74 subjects were randomized (33 phlebotomy and 41 control). The phlebotomy group underwent a median (range) of 7 (1-19) venesection sessions and had a significantly greater reduction in ferritin levels over 6 months, compared to controls (-148±114 vs. -38±89 ng/mL; P

U2 - 10.1002/hep.27662

DO - 10.1002/hep.27662

M3 - Article

VL - 61

SP - 1555

EP - 1564

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -

Access to Document

10.1002/hep.27662